2. Academic Validation
  3. Antibody Engineering for Nuclear Imaging and Radioimmunotherapy

Antibody Engineering for Nuclear Imaging and Radioimmunotherapy

  • J Nucl Med. 2022 Sep;63(9):1316-1322. doi: 10.2967/jnumed.122.263861.
Cindy Rodriguez 1 2 3,  Samantha Delaney 1 3 4,  Samantha M Sarrett 1 3 4,  Outi M Keinänen 1 3 5,  Brian M Zeglis 6 2 3 4 7
Affiliations

Affiliations

  • 1 Department of Chemistry, Hunter College, City University of New York, New York, New York.
  • 2 Ph.D. Program in Chemistry, Graduate Center of City University of New York, New York, New York.
  • 3 Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • 4 Ph.D. Program in Biochemistry, Graduate Center of City University of New York, New York, New York.
  • 5 Department of Chemistry, University of Helsinki, Helsinki, Finland; and.
  • 6 Department of Chemistry, Hunter College, City University of New York, New York, New York; [email protected].
  • 7 Department of Radiology, Weill Cornell Medical College, New York, New York.
PMID: 35863894 DOI: 10.2967/jnumed.122.263861
Abstract

Radiolabeled antibodies have become indispensable tools in nuclear medicine. However, the natural roles of antibodies within the immune system mean that they have several intrinsic limitations as a platform for radiopharmaceuticals. In recent years, the field has increasingly turned to antibody engineering to circumvent these issues while retaining the manifold benefits of the immunoglobulin framework. In this "Focus on Molecular Imaging" review, we cover recent advances in the application of antibody engineering to immunoPET, immunoSPECT, and radioimmunotherapy. Specifically, we address how antibody engineering has been used to improve radioimmunoconjugates on four fronts: optimizing pharmacokinetics, facilitating site-specific bioconjugation, modulating Fc interactions, and creating bispecific constructs.

Keywords

Fc receptor; PET; antibody; antibody engineering; antibody fragment; radioimmunotherapy.

Figures